MedTrace Logo

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

NCT02152332 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2014-11-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals in healthy participants, when administered at therapeutic (50 milligram \[mg\] once-daily) and supratherapeutic (150 mg once-daily) doses for 7 days.

Conditions

  • Healthy

Interventions

DRUG

JNJ-54861911-Therapeutic Dose

JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

DRUG

JNJ-54861911 - Supratherapeutic Dose

JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

DRUG

JNJ-54861911-Matched Placebo

JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

DRUG

Moxifloxacin

Moxifloxacin 400 mg on Day 7 in all treatment sequence.

DRUG

Moxifloxacin Matched Placebo

Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trials · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02152332 on ClinicalTrials.gov